Jean‐Luc Harousseau

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal et al. · New England Journal of Medicine · 2007 · 1.5K citations

Medicine, Pharmacology, Pharmacotherapy +14

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar, Jean‐Luc Harousseau, Brian G.M. Durie et al. · Blood · 2011 · 1K citations · Full text

Medicine, Hematology, Oncology +13

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 645 citations · Full text

Medicine, Oncology, Pharmacology +17

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

Asher Chanan‐Khan, Pieter Sonneveld, Michael W. Schuster et al. · Journal of Clinical Oncology · 2008 · 266 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +10

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Heinz Ludwig, Brian G.M. Durie, Vanessa Bolejack et al. · Blood · 2008 · 234 citations · Full text

Medicine, Hematology, Oncology +12